UCB SA, of Brussels, said the FDA has accepted for review the new drug application for brivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients from 16 years of age with epilepsy, and in the EU, the EMA has validated for review the marketing authorization application for brivaracetam in the same proposed indication.